BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 27, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

MN-221: Final Phase II data

Final data from 29 patients in a single-blind, U.S. Phase II trial (MN-221-CL-006) showed that the hospitalization rate was 25% in patients receiving MN-221 plus SOC vs. 46% for SOC alone. SOC consisted of inhaled albuterol, ipratropium and oral steroid treatment....

Read the full 182 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >